Gastrointestinal Disorders Associated with Autism Spectrum Disorder
V. O. Generalov,
T. P. Klyushnik,
T. E. Obodzinskaya,
A. N. Aleksandrenkova,
T. R. Sadykov,
G. V. Larionov https://doi.org/10.31550/1727-2378-2024-237-86-91
Abstract
Aim. A synthesis of scientific literature data on the association of autism spectrum disorders (ASD) with gastrointestinal dysfunction and disturbances of the intestinal microbiota.
Key points. ASDs belong to a group of neurodevelopmental disorders associated with genetic, epigenetic and environmental factors, and include conditions that are heterogeneous in clinical presentation and severity of psychopathological symptoms. ASD is often comes with various symptoms of gastrointestinal tract dysfunction referred to impaired intestinal barrier permeability. The consequence is the pervasion of external agents (food antigens, toxins, bacterial metabolites) into the blood and initiation or maintenance of the inflammatory process, which is the most important pathophysiological link in ASD. Particular attention is paid to the analysis of the mechanisms of impaired intestinal barrier permeability. It is necessary to develop strategies aimed at reducing the level of inflammation in complex therapy of patients with ASD.
Conclusion. Patients with ASD, in addition to psychoneurological symptoms, often present somatic problems, which, however, may not be timely recognized due to their nonspecificity and the difficulty of differentiating behavioral reactions either associated with the disorder or being just a reaction to somatic ill-being.Moreover, the whole complex of clinical manifestations is mediated by a single systemic dysregulation of immunological and metabolic reactions and is inherently a different reflection of one process, requiring profound multidisciplinary treatment and the use of various therapy approaches.
About the Authors
V. O. Generalov
Center "PlanetaMed"
Russian Federation
Russian Federation
Moscow
T. P. Klyushnik
Center "PlanetaMed"
Russian Federation
Russian Federation
Moscow
T. E. Obodzinskaya
Center "PlanetaMed"
Russian Federation
Russian Federation
Moscow
A. N. Aleksandrenkova
Center "PlanetaMed"
Russian Federation
Russian Federation
Moscow
T. R. Sadykov
Center "PlanetaMed"
Russian Federation
Russian Federation
Moscow
G. V. Larionov
Center "PlanetaMed"
Russian Federation
Russian Federation
Moscow
References
1. Lasheras I., Real-López M., Santabárbara J. Prevalence of gastrointestinal symptoms in autism spectrum disorder: a meta-analysis. Anales de Pediatría (English Edition). 2023;99(Suppl.2):102–10. DOI: 10.1016/j.anpede.2023.07.003
2. Arteaga-Henriquez G., Gisbert L., Ramos-Quiroga J.A. Immunoregulatory and/or anti-inflammatory agents for the management of core and associated symptoms in individuals with autism spectrum disorder: a narrative review of randomized, placebo-controlled trials. CNS Drugs. 2023;37(3):215–29. DOI: 10.1007/s40263-023-00993-x
3. Gładysz D., Krzywdzińska A., Hozyasz K.K. Immune abnormalities in autism spectrum disorder-could they hold promise for causative treatment? Mol. Neurobiol. 2018;55(8):6387–435. DOI: 10.1007/s12035-017-0822-x
4. Obodzinskaya T.E., Generalov V.O., Sadykov T.R., Aleksandrenkova A.A. et al. Neuroinflammation process as a key etiopathogenetic factor in the evolution of autism syndrome in child patients. Psikhiatriya. 2023;21(5):47–55. (in Russian). DOI: 10.30629/2618-6667-2023-21-5-47-55
5. Chaidez V., Hansen R.L., Hertz-Picciotto I. Gastrointestinal problems in children with autism, developmental delays or typical development. J. Autism Dev. Disord. 2014;44(5):1117–27. DOI: 10.1007/s10803-013-1973-x
6. Adams J.B., Johansen L.J., Powell L.D., Quig D. et al. Gastrointestinal flora and gastrointestinal status in children with autism–comparisons to typical children and correlation with autism severity. BMC Gastroenterol. 2011;11:22. DOI: 10.1186/1471-230X-11-22
7. De Magistris L., Familiari V., Pascotto A., Sapone A. et al. Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. J. Pediat. Gastroenterol. Nutr. 2010;51(4):418–24. DOI: 10.1097/MPG.0b013e3181dcc4a5
8. Babinská K., Tomova A., Celušáková H., Babková J. et al. Fecal calprotectin levels correlate with main domains of the autism diagnostic interview-revised (ADI-R) in a sample of individuals with autism spectrum disorders from Slovakia. Physiol. Res. 2017;66(Suppl.4):S517–22. DOI: 10.33549/physiolres.933801
9. Dash S., Syed Y.A., Khan M.R. Understanding the role of the gut microbiome in brain development and its association with neurodevelopmental psychiatric disorders. Front. Cell Dev. Biol. 2022;10:880544. DOI: 10.3389/fcell.2022.880544
10. Garcia-Gutierrez E., Narbad A., Rodríguez J.M. Autism spectrum disorder associated with gut microbiota at immune, metabolomic, and neuroactive level. Front. Neurosci. 2020;14:578666. DOI: 10.3389/fnins.2020.578666
11. Xu M., Xu X., Li J., Li F. et al. Association between gut microbiota and autism spectrum disorder: a systematic review and meta-analysis. Front. Psychiatry. 2019;10:473. DOI: 10.3389/fpsyt.2019.00473
12. Polyakova S.I., Bystrova O.V., Agudin P.S., Parshina P.V. et al. Composition of gut microbiota in children with autism spectrum disorders according to mass spectrometry of microbial markers. Pediatric Nutrition. 2021;19(6):5–15. (in Russian). DOI: 10.20953/1727-5784-2021-6-5-15
13. Strati F., Cavalieri D., Albanese D., De Felice C. et al. New evidences on the altered gut microbiota in autism spectrum disorders. Microbiome. 2017;5(1):24. DOI: 10.1186/s40168-017-0242-1
14. De Angelis M., Francavilla R., Piccolo M., De Giacomo A. et al. Autism spectrum disorders and intestinal microbiota. Gut Microbes. 2015;6(3):207–13. DOI: 10.1080/19490976.2015.1035855
15. Iovene M.R., Bombace F., Maresca R., Sapone A. et al. Intestinal dysbiosis and yeast isolation in stool of subjects with autism spectrum disorders. Mycopathologia. 2017;182(3–4):349–63. DOI: 10.1007/s11046-016-0068-6
16. Shindler A.E., Hill-Yardin E., Petrovski S., Cunningham A.C. et al. Potential determinants of gastrointestinal dysfunction in autism spectrum disorders. Review Journal of Autism and Developmental Disorders. 2020;7:182–96. DOI: 10.1007/s40489-019-00187-6
17. Wang L., Yu Y.M., Zhan Y.Q., Zhang J. et al. Hydrogen breath test to detect small intestinal bacterial overgrowth: a prevalence case–control study in autism. Eur. Child Adolesc. Psychiatry. 2018;27(2):233–40. DOI: 10.1007/s00787-017-1039-2
18. Venegas D.P., De la Fuente M.K., Landskron G., González M.J. et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front. Immunol. 2019;10:277. DOI: 10.3389/fimmu.2019.00277
19. Al-Ayadhi L., Zayed N., Bhat R.Sh., Moubayed N.M.S. et al. The use of biomarkers associated with leaky gut as a diagnostic tool for early intervention in autism spectrum disorder: a systematic review. Gut Pathog. 2021;13(1):54. DOI: 10.1186/s13099-021-00448-y
20. Ratajczak W., Rył A., Mizerski A., Walczakiewicz K. et al. Immunomodulatory potential of gut microbiome-derived shortchain fatty acids (SCFAs). Acta Biochim. Pol. 2019;66(1):1–12. DOI: 10.18388/abp.2018_2648
21. Esnafoglu E., Cırrık S., Ayyıldız S.N., Erdil A. et al. Increased serum zonulin levels as an intestinal permeability marker in autistic subjects. J. Pediatr. 2017;188:240–4. DOI: 10.1016/j.jpeds.2017.04.004
22. Roe K. Autism spectrum disorder initiation by inflammationfacilitated neurotoxin transport. Neurochem. Res. 2022;47(5): 1150–65. DOI: 10.1007/s11064-022-03527-x
23. Eshraghi R.S., Davies C., Iyengar R., Perez L. et al. Gut-induced inflammation during development may compromise the blood-brain barrier and predispose to autism spectrum disorder. J. Clin. Med. 2020;10(1):27. DOI: 10.3390/jcm10010027
24. Emanuele E., Orsi P., Boso M., Broglia D. et al. Low-grade endotoxemia in patients with severe autism Neurosci. Lett. 2010;471(3):162–5. DOI: 10.1016/j.neulet.2010.01.033
25. Jyonouchi H., Geng L., Ruby A., Zimmerman-Bier B. Dysregulated innate immune responses in young children with autism spectrum disorders: their relationship to gastrointestinal symptoms and dietary intervention. Neuropsychobiology. 2005;51(2):77–85. DOI: 10.1159/000084164
26. Trajkovski V., Petlichkovski A., Efinska-Mladenovska O., Trajkov D. et al. Higher plasma concentration of food-specific antibodies in persons with autistic disorder in comparison to their siblings. Focus Autism Other Dev. Disabl. 2008;23(3):176–85. DOI: 10.1177/1088357608320413
27. De Magistris L., Picardi A., Siniscalco D., Riccio M.P. et al. Antibodies against food antigens in patients with autistic spectrum disorders. BioMed Res. Int. 2013;2013:729349. DOI: 10.1155/2013/729349
28. Jyonouchi H., Sun S., Itokazu N. Innate immunity associated with inflammatory responses and cytokine production against common dietary proteins in patients with autism spectrum disorder. Neuropsychobiology. 2002;46(2):76–84. DOI: 10.1159/000065416
29. Vojdani A., Gushgari L. R., Vojdani E. Interaction between food antigens and the immune system: association with autoimmune disorders. Autoimmun. Rev. 2020;19(3):102459. DOI: 10.1016/j.autrev.2020.102459
30. Roe K. How major fungal infections can initiate severe autoimmune disease. Microb. Pathog. 2021;161(Pt.A):105200. DOI: 10.1016/j.micpath.2021.105200
31. Vojdani A. Molecular mimicry as a mechanism for food immune reactivities and autoimmunity. Altern. Ther. Health Med. 2015;21(Suppl.1):34–45.
32. Vojdani A., Campbell A.W., Anyanwu E., Kashanian A. et al. Antibodies to neuron-specific antigens in children with autism: possible crossreaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A. J. Neuroimmunol. 2002;129(1–2):168–77. DOI: 10.1016/s0165-5728(02)00180-7
33. Sollid L.M., Jabri B. Triggers and drivers of autoimmunity: lessons from coeliac disease. Nat. Rev. Immunol. 2013;13(4):294–302. DOI: 10.1038/nri3407
34. Asadabadi M., Mohammadi M.R., Ghanizadeh A., Modabbernia A. et al. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebocontrolled trial. Psychopharmacology. 2013;225(1):51–9. DOI: 10.1007/s00213-012-2796-8.
35. Malek M., Ashraf-Ganjouei A., Moradi K., Bagheri S. et al. Prednisolone as adjunctive treatment to risperidone in children with regressive type of autism spectrum disorder: a randomized, placebo-controlled trial. Clin. Neuropharmacol. 2020;43(2):39–45. DOI: 10.1097/WNF.0000000000000382
36. Ayatollahi A., Bagheri S., Ashraf-Ganjouei A., Moradi K. et al. Does pregnenolone adjunct to risperidone ameliorate irritable behavior in adolescents with autism spectrum disorder: a randomized, doubleblind, placebo-controlled clinical trial? Clin. Neuropharmacol. 2020;43(5):139–45. DOI: 10.1097/WNF.0000000000000405
37. Ghaleiha A., Alikhani R., Kazemi M.R., Mohammadi M.R. et al. Minocycline as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind placebo-controlled trial. J. Child Adolesc. Psychopharmacol. 2016;26(9):784–91. DOI: 10.1089/cap.2015.0175
38. Zvyagin A.A., Bavykina I.A. Gluten-free diet effectiveness in treatment of autism spectrum disorders in children. Pediatria. 2017;96(6):197–200. (in Russian). DOI: 10.24110/0031-403X-2017-96-6-197-200
39. Ghalichi F., Ghaemmaghami J., Malek A., Ostadrahimi A. Effect of gluten free diet on gastrointestinal and behavioral indices for children with autism spectrum disorders: a randomized clinical trial. World J. Pediatr. 2016;12(4):436–42. DOI: 10.1007/s12519-016-0040-z
40. Varesio C., Grumi S., Zanaboni M.P., Mensi M.M. et al. Ketogenic dietary therapies in patients with autism spectrum disorder: facts or fads? A scoping review and a proposal for a shared protocol. Nutrients. 2021;13(6):2057. DOI: 10.3390/nu13062057
41. Yu Y., Huang J., Chen X., Fu J. et al. Efficacy and safety of diet therapies in children with autism spectrum disorder: a systematic literature review and meta-analysis. Front. Neurol. 2022;13:844117. DOI: 10.3389/fneur.2022.844117
Review
For citations:
Generalov V.O., Klyushnik T.P., Obodzinskaya T.E., Aleksandrenkova A.N., Sadykov T.R., Larionov G.V. Gastrointestinal Disorders Associated with Autism Spectrum Disorder. Title. 2024;23(7):86-91. (In Russ.) https://doi.org/10.31550/1727-2378-2024-237-86-91
Views:
6
Email this article 